Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci191370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Zheng Zhong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore. Hauptthemen laut MEDLINE: GATA6 Transcription Factor, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), MAP Kinase Signaling System. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Medical Research Council, National Cancer Institute.
Abstract (Originalsprache)
GATA6 is a master regulator of differentiation in the pancreas, and its expression levels determine the 2 main molecular subtypes of pancreatic cancer. High GATA6 levels contribute to the classical pancreatic cancer subtype, which is associated with a higher degree of tumor differentiation and better disease prognosis. However, why GATA6 expression varies across pancreatic cancers and what regulates GATA6 expression remain elusive. Here, we report that oncogenic KRAS-activated ERK signaling suppresses GATA6 transcription in pancreatic cancers. GATA6 mRNA levels inversely correlated with KRAS/ERK activity in pancreatic tumors. A genome-wide CRISPR screen in a GATA6 - EGFP reporter knockin cell line identified JUNB as the ERK-regulated transcriptional repressor for GATA6 . Active ERK stabilized JUNB protein, while KRAS/ERK inhibition led to ubiquitin-independent proteasomal degradation of JUNB and increased transcription of GATA6 . Upregulation of GATA6 enhanced chemosensitivity of pancreatic cancer cells, and KRAS/ERK inhibitors synergized with chemotherapy in a GATA6-dependent manner. Our study identifies how oncogenic KRAS/ERK signaling suppresses GATA6 to cause dedifferentiation in pancreatic cancer. Combining KRAS/ERK inhibitors with standard-of-care chemotherapies could be a promising therapeutic strategy for treating pancreatic cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.
- Genome Institute of Singapore and.
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore.
- Lineberger Comprehensive Cancer Center and.
- Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Centre for Computational Biology, Duke-NUS Medical School, Singapore.
Förderung
- NCI NIH HHS
- National Medical Research Council
- National Cancer Institute
- Pancreatic Cancer Action Network
- U.S. Department of Defense
Zitieren
APA
Zhong, Z., Cao, X., Liao, P. J., Sethi, R., Klomp, J. A., Stalnecker, C. A., Chen, J., Wan, Y., Der, C. J., & Virshup, D. M. (2026). Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci191370
Vancouver
Zhong Z, Cao X, Liao PJ, Sethi R, Klomp JA, Stalnecker CA, et al. Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer. Journal of Clinical Investigation. 2026. doi:10.1172/jci191370
BibTeX
@article{Zhong2026,
author = {Zhong, Zheng and Cao, Xinang and Liao, Pei-Ju and Sethi, Raman and Klomp, Jeffrey A and Stalnecker, Clint A and Chen, Jinmiao and Wan, Yue and Der, Channing J and Virshup, David M},
title = {Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci191370}
}
EUVIMED